Overview

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Status:
Completed
Trial end date:
1993-02-01
Target enrollment:
0
Participant gender:
All
Summary
The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Losartan
Criteria
Inclusion Criteria:

- Patient has been diagnosed with mild to moderate hypertension

- Patient has no treatment or active medical problem, other than hypertension that might
affect the patients blood pressure

Exclusion Criteria:

- Pregnant of lactating female patients

- Secondary hypertension or history of malignant hypertension

- Sitting systolic blood pressure > 210 mmHg

- History of stroke

- History of myocardial infarction with in the past year

- Current of prior history of heart failure

- Known hypersensitivity to losartan

- Obesity

- Patients known to be HIV positive or known to be positive for Hepatitis B

- Absence of one kidney

- Patient is abusing or previously abused alcohol or drugs with in past two years